Gene · 5732
Papers3,629
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,629
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities. | Biomark Res | 2024 | 38185636 | PubTator, text mining | PubMed |
| Genetic Modification of Aurantiochytrium sp. 18W-13a for Enhancement of Proteolytic Activity by Heterologous Expression of Extracellular Proteases. | Mar Biotechnol (NY) | 2024 | 38180637 | PubTator, text mining | PubMed |
| Prodigiosin/celecoxib-loaded into zein/sodium caseinate nanoparticles as a potential therapy for triple negative breast cancer. | Sci Rep | 2024 | 38168547 | PubTator, text mining | PubMed |
| PGE2-EP4 signaling steers cDC2 maturation toward the induction of suppressive T-cell responses. | Eur J Immunol | 2024 | 38088451 | PubTator, text mining | PubMed |
| N-acetyl cysteine turns EPAC activators into potent killers of acute lymphoblastic leukemia cells. | J Biol Chem | 2024 | 38042493 | PubTator, text mining | PubMed |
| Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors. | ChemMedChem | 2024 | 37983645 | PubTator, text mining | PubMed |
| Phoenixin-14 as a novel direct regulator of porcine luteal cell functions†. | Biol Reprod | 2024 | 37815939 | PubTator, text mining | PubMed |
| Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. | Neural Regen Res | 2024 | 37488851 | PubTator, text mining | PubMed |
| Computational Insights into Prostaglandin E2 Ligand Binding and Activation of G-Protein-Coupled Receptors. | ACS Appl Bio Mater | 2024 | 37058420 | PubTator, text mining | PubMed |
| Mechanobiology in cellular, molecular, and tissue adaptation. | Mechanobiol Med | 2023 | 40395638 | PubTator, text mining | PubMed |
| Genetic deletion of 12/15 lipoxygenase delays vascular remodeling and limits cardiorenal dysfunction after pressure overload. | J Mol Cell Cardiol Plus | 2023 | 39802176 | PubTator, text mining | PubMed |
| Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. | Thromb Update | 2023 | 38620822 | PubTator, text mining | PubMed |
| Evaluation of the effects of latanoprost and benzalkonium chloride on the cell viability and nonpolar lipid profile produced by human meibomian gland epithelial cells in culture. | Mol Vis | 2023 | 38264609 | PubTator, text mining | PubMed |
| Potential causal association between aspirin use and erectile dysfunction in European population: a Mendelian randomization study. | Front Endocrinol (Lausanne) | 2023 | 38260164 | PubTator, text mining | PubMed |
| Current understanding of macrophages in intracranial aneurysm: relevant etiological manifestations, signaling modulation and therapeutic strategies. | Front Immunol | 2023 | 38259443 | PubTator, text mining | PubMed |
| Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer. | Curr Issues Mol Biol | 2023 | 38248312 | PubTator, text mining | PubMed |
| Tissue lipidomic profiling supports a mechanistic role of the prostaglandin E2 pathway for albuminuria development in glomerular hyperfiltration. | Front Netw Physiol | 2023 | 38205443 | PubTator, text mining | PubMed |
| Effect of Thermomechanical Loading at Low Temperatures on Damage Development in Glass Fiber Epoxy Laminates. | Materials (Basel) | 2023 | 38203870 | PubTator, text mining | PubMed |
| Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer. | Cancers (Basel) | 2023 | 38201508 | PubTator, text mining | PubMed |
| Preparation of High-Transparency Phosphenanthrene-Based Flame Retardants and Studies of Their Flame-Retardant Properties. | Polymers (Basel) | 2023 | 38139917 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5732/papers?page=9